Systemic therapy for bladder cancer - a medical oncologist's perspective

Journal of Solid Tumors

Volumn 4, Issue 2, 2014, Pages 25-35

  Teply, Benjamin A ^a   Kim, Jenny J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Bladder Cancer; Chemotherapy; Cisplatin; Metastatic; Neoadjuvant

Indexed keywords

AMIFOSTINE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PEMETREXED; TRASTUZUMAB; VINBLASTINE; VINFLUNINE;

ADVANCED CANCER; BLADDER CANCER; BLADDER PRESERVATION; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CHEMORADIOTHERAPY; COMORBIDITY; CYSTECTOMY; FEBRILE NEUTROPENIA; HUMAN; KIDNEY FAILURE; LYMPH NODE DISSECTION; METASTASIS RESECTION; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; NEPHROTOXICITY; NEUTROPENIA; ORGAN PRESERVATION; OVERALL SURVIVAL; PATIENT SELECTION; RECURRENCE FREE SURVIVAL; REVIEW; SEPSIS; SURVIVAL RATE; TRANSURETHRAL RESECTION; TUMOR RECURRENCE;

EID: 84929410921     PISSN: 19254067     EISSN: 19254075     Source Type: Journal    
DOI: 10.5430/jst.v4n2p25     Document Type: Review

References (71)

1. Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nat Rev Urol. 2014; 11: 153-62. PMid:24492433 http://dx.doi.org/10.1038/nrurol.2014.15
2. Barlow LJ, Benson MC. Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer. Curr Urol Rep. 2013; 14:65-70. PMid:23378162 http://dx.doi.org/10.1007/s11934-013-0312-2
3. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19:666-75. PMid:11157016
4. Goodfellow H, Viney Z, Hughes P, et al. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int. 2014. PMid:24341486 http://dx.doi.org/10.1111/bju.12608
5. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009; 55:164-74. PMid:18675501 http://dx.doi.org/10.1016/j.eururo.2008.07.031
6. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-66, 2003. PMid:12944571 http://dx.doi.org/10.1056/NEJMoa022148
7. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999; 354: 533-40. http://dx.doi.org/10.1016/S0140-6736(99)02292-8
8. Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol. 2011; 29: 2171-7. PMid:21502557 http://dx.doi.org/10.1200/JCO.2010.32.3139
9. Herchenhorn D, Dienstmann R, Peixoto FA, et al. Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. Int Braz J Urol. 2007; 33:630-8; discussion 638. PMid:17980060 http://dx.doi.org/10.1590/S1677-55382007000500004
10. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001; 19:2638-46. PMid:11352955
11. deVere White RW, Lara PN, Jr., Goldman B, et al. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol. 2009; 181:2476-80; discussion 2480-1. PMid:19371909 http://dx.doi.org/10.1016/j.juro.2009.01.115
12. Smith DC, Mackler NJ, Dunn RL, et al. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol. 2008; 180:2384-8; discussion 2388. PMid:18930256 http://dx.doi.org/10.1016/j.juro.2008.08.075
13. Grivas PD, Hussain M, Hafez K, et al. A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder. Urology. 2013; 82:111-7. PMid:23706253 http://dx.doi.org/10.1016/j.urology.2013.03.044
14. Stockle M, Meyenburg W, Wellek S, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol. 1992; 148:302-6; discussion 306-7. PMid:1635123
15. Stockle M, Meyenburg W, Wellek S, et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol. 1995; 153:47-52. PMid:7966789 http://dx.doi.org/10.1097/00005392-199501000-00019
16. Cognetti F, Ruggeri EM, Felici A, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol. 2012; 23:695-700. PMid:21859900 http://dx.doi.org/10.1093/annonc/mdr354
17. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005; 48:189-199; discussion 199-201. PMid:15939530 http://dx.doi.org/10.1016/j.eururo.2005.04.005
18. Booth CM, Siemens DR, Li G, et al. Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study. Cancer, 2014. PMid:24733278 http://dx.doi.org/10.1002/cncr.28510
19. Zietman AL, Shipley WU, Kaufman DS. The combination of cis-platin based chemotherapy and radiation in the treatment of muscle-invading transitional cell cancer of the bladder. Int J Radiat Oncol Biol Phys. 1993; 27:161-70. http://dx.doi.org/10.1016/0360-3016(93)90434-W
20. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012; 366:1477-88. PMid:22512481 http://dx.doi.org/10.1056/NEJMoa1106106
21. Kaufman DS, Shipley WU, Griffin PP, et al. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med. 1993; 329:1377-82. PMid:8413433 http://dx.doi.org/10.1056/NEJM199311043291903
22. Gogna NK, Matthews JH, Turner SL, et al. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol. 2006; 81:9-17. PMid:17011058 http://dx.doi.org/10.1016/j.radonc.2006.09.001
23. Choudhury A, Swindell R, Logue JP, et al. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol. 2011; 29:733-8. PMid:21205754 http://dx.doi.org/10.1200/JCO.2010.31.5721
24. Kragelj B, Zaletel-Kragelj L, Sedmak B, et al. Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer. Radiother Oncol. 2005; 75:44-7. PMid:15878100 http://dx.doi.org/10.1016/j.radonc.2005.01.007
25. Panteliadou M, Giatromanolaki A, Touloupidis S, et al. Treatment of invasive bladder cancer with conformal hypofractionated accelerated radiotherapy and amifostine (HypoARC). Urol Oncol. 2012; 30: 813-20. PMid:21163674 http://dx.doi.org/10.1016/j.urolonc.2010.09.001
26. Panteliadou M, Touloupidis S, Giatromanolaki A, et al. Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC). Med Oncol. 2011; 28: 1356-62. PMid:20424934 http://dx.doi.org/10.1007/s12032-010-9544-x
27. Mitin T, Hunt D, Shipley WU, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 2013; 14: 863-72. http://dx.doi.org/10.1016/S1470-2045(13)70255-9
28. Hussain MH, Glass TR, Forman J, et al. Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol. 2001; 165:56-60; discussion 60-1. PMid:11125363 http://dx.doi.org/10.1097/00005392-200101000-00014
29. Hoskin P, Rojas A, Saunders M: Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a Phase II nonrandomized study. Int J Radiat Oncol Biol Phys. 2009; 73:1425-31. PMid:19036531 http://dx.doi.org/10.1016/j.ijrobp.2008.06.1950
30. Lagrange JL, Bascoul-Mollevi C, Geoffrois L, et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). Int J Radiat Oncol Biol Phys. 2011; 79:172-8. PMid:20385453 http://dx.doi.org/10.1016/j.ijrobp.2009.10.038
31. Herman JM, Smith DC, Montie J, et al. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology. 2004; 64:69-73. PMid:15245938 http://dx.doi.org/10.1016/j.urology.2004.02.024
32. Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol. 2009; 27:4055-61. PMid:19636019 http://dx.doi.org/10.1200/JCO.2008.19.5776
33. Loehrer PJ, Sr., Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992; 10:1066-73. PMid:1607913
34. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006; 42:50-4. PMid:16330205 http://dx.doi.org/10.1016/j.ejca.2005.08.032
35. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18:3068-77. PMid:11001674
36. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23:4602-8. PMid:16034041 http://dx.doi.org/10.1200/JCO.2005.07.757
37. Bamias A, Dafni U, Karadimou A, et al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann Oncol. 2013; 24:1011-7. PMid:23136231 http://dx.doi.org/10.1093/annonc/mds583
38. Burch PA, Richardson RL, Cha SS, et al. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol. 2000; 164:1538-42. http://dx.doi.org/10.1016/S0022-5347(05)67023-1
39. Garcia del Muro X, Marcuello E, Guma J, et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer. 2002; 86: 326-30. PMid:11875692 http://dx.doi.org/10.1038/sj.bjc.6600121
40. Bellmunt J, von der Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012; 30:1107-13. PMid:22370319 http://dx.doi.org/10.1200/JCO.2011.38.6979
41. Hutson TE, Vukelja S, Atienza D, et al. Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. Invest New Drugs. 2008; 26:151-8. PMid:18236006 http://dx.doi.org/10.1007/s10637-007-9111-2
42. Boukovinas I, Androulakis N, Kentepozidis N, et al. Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemother Pharmacol. 2012; 69:351-6. PMid:21748359 http://dx.doi.org/10.1007/s00280-011-1694-9
43. Linardou H, Aravantinos G, Efstathiou E, et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology. 2004; 64: 479-84. PMid:15351574 http://dx.doi.org/10.1016/j.urology.2004.04.024
44. Bamias A, Moulopoulos LA, Koutras A, et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer. 2006; 106:297-303. PMid:16342065 http://dx.doi.org/10.1002/cncr.21604
45. Eroglu Z, Fruehauf JP. A phase II study of gemcitabine and oxaliplatin in advanced transitional cell carcinoma of the bladder. Cancer Chemother Pharmacol. 2013; 72:263-7. PMid:23636451 http://dx.doi.org/10.1007/s00280-013-2178-x
46. Carles J, Esteban E, Climent M, et al. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol. 2007; 18:1359-62. PMid:17693649 http://dx.doi.org/10.1093/annonc/mdm160
47. Culine S, Flechon A, Guillot A, et al. Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01). Eur Urol. 2011; 60:1251-7. PMid:21924547 http://dx.doi.org/10.1016/j.eururo.2011.08.072
48. Dogliotti L, Carteni G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol. 2007; 52:134-41. PMid:17207911 http://dx.doi.org/10.1016/j.eururo.2006.12.029
49. Hainsworth JD, Meluch AA, Litchy S, et al. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer. 2005; 103:2298-303. PMid:15856431 http://dx.doi.org/10.1002/cncr.21078
50. Kattan JG, Boutros CY, Farhat FS, et al. Sequential therapy with gemcitabine and Carboplatin followed by Paclitaxel as first line treatment for advanced urothelial cancer. J Cancer. 2012; 3:362-8. PMid:23074377 http://dx.doi.org/10.7150/jca.4224
51. Galsky MD, Iasonos A, Mironov S, et al. Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. Cancer. 2007; 109:549-55. PMid:17200962 http://dx.doi.org/10.1002/cncr.22454
52. Tsavaris N, Kosmas C, Skopelitis H, et al. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study. J Chemother. 2005; 17:441-8. PMid:16167525 http://dx.doi.org/10.1179/joc.2005.17.4.444
53. Halim A, Abotouk N. Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study. Asia Pac J Clin Oncol. 2013; 9:60-5. PMid:22897883 http://dx.doi.org/10.1111/j.1743-7563.2012.01554.x
54. Dumez H, Martens M, Selleslach J, et al. Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study. Anticancer Drugs. 2007; 18:211-8. PMid:17159607 http://dx.doi.org/10.1097/CAD.0b013e328010ee5c
55. Dreicer R, Li H, Cooney MM, et al. Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. Cancer. 2008; 112:2671-5. PMid:18459175 http://dx.doi.org/10.1002/cncr.23503
56. Neri B, Doni L, Fulignati C, et al. Gemcitabine plus Epi-doxorubicin as first-line chemotherapy for bladder cancer in advanced or metastatic stage: a phase II. Anticancer Res. 2002; 22:2981-4. PMid:12530029
57. Turkolmez K, Beduk Y, Baltaci S, et al. Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy. Eur Urol. 2003; 44:682-6. http://dx.doi.org/10.1016/S0302-2838(03)00385-3
58. Dodd PM, McCaffrey JA, Herr H, et al: Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol. 1999; 17:2546-52. PMid:10561321
59. Siefker-Radtke AO, Walsh GL, Pisters LL, et al. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol. 2004; 171:145-8. PMid:14665863 http://dx.doi.org/10.1097/01.ju.0000099823.60465.e6
60. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009; 27:4454-61. PMid:19687335 http://dx.doi.org/10.1200/JCO.2008.20.5534
61. Bellmunt J, Fougeray R, Rosenberg JE, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol. 2013; 24:1466-72. PMid:23419284 http://dx.doi.org/10.1093/annonc/mdt007
62. Albers P, Park SI, Niegisch G, et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol. 2011; 22:288-94. PMid:20682548 http://dx.doi.org/10.1093/annonc/mdq398
63. Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011; 29: 1525-30. PMid:21422406 http://dx.doi.org/10.1200/JCO.2010.31.6067
64. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007; 25:2218-24. PMid:17538166 http://dx.doi.org/10.1200/JCO.2006.08.0994
65. Kim JJ. Recent advances in treatment of advanced urothelial carcinoma. Curr Urol Rep. 2012; 13:147-52. PMid:22367511 http://dx.doi.org/10.1007/s11934-012-0238-0
66. Zhu Z, Shen Z, Xu C. Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Mediators Inflamm. 2012:Article ID 528690
67. Akaza H, Naito S, Usami M, et al. Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience. Jpn J Clin Oncol. 2007; 37:201-6. PMid:17452426 http://dx.doi.org/10.1093/jjco/hym011
68. Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006; 24:3451-7. PMid:16849761 http://dx.doi.org/10.1200/JCO.2005.03.6699
69. Ko YJ, Canil CM, Mukherjee SD, et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. Lancet Oncol. 2013; 14:769-76. http://dx.doi.org/10.1016/S1470-2045(13)70162-1
70. Kouno T, Ando M, Yonemori K, et al. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol. 2007; 52: 1115-22. PMid:17433855 http://dx.doi.org/10.1016/j.eururo.2007.03.078
71. Rozzi A, Santini D, Salerno M, et al. Pegylated liposomal doxorubicin as third-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study. Med Oncol. 2013; 30:407. PMid:23307245 http://dx.doi.org/10.1007/s12032-012-0407-5